1. Home
  2. ACET vs INTT Comparison

ACET vs INTT Comparison

Compare ACET & INTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACET
  • INTT
  • Stock Information
  • Founded
  • ACET 1947
  • INTT 1981
  • Country
  • ACET United States
  • INTT United States
  • Employees
  • ACET N/A
  • INTT N/A
  • Industry
  • ACET Biotechnology: Pharmaceutical Preparations
  • INTT Semiconductors
  • Sector
  • ACET Health Care
  • INTT Technology
  • Exchange
  • ACET Nasdaq
  • INTT Nasdaq
  • Market Cap
  • ACET 64.9M
  • INTT 77.3M
  • IPO Year
  • ACET N/A
  • INTT 1997
  • Fundamental
  • Price
  • ACET $0.67
  • INTT $6.93
  • Analyst Decision
  • ACET Buy
  • INTT Strong Buy
  • Analyst Count
  • ACET 6
  • INTT 2
  • Target Price
  • ACET $6.00
  • INTT $12.00
  • AVG Volume (30 Days)
  • ACET 412.2K
  • INTT 35.7K
  • Earning Date
  • ACET 08-12-2025
  • INTT 08-01-2025
  • Dividend Yield
  • ACET N/A
  • INTT N/A
  • EPS Growth
  • ACET N/A
  • INTT N/A
  • EPS
  • ACET N/A
  • INTT N/A
  • Revenue
  • ACET N/A
  • INTT $127,503,000.00
  • Revenue This Year
  • ACET N/A
  • INTT N/A
  • Revenue Next Year
  • ACET N/A
  • INTT $10.07
  • P/E Ratio
  • ACET N/A
  • INTT N/A
  • Revenue Growth
  • ACET N/A
  • INTT 5.19
  • 52 Week Low
  • ACET $0.45
  • INTT $5.24
  • 52 Week High
  • ACET $1.70
  • INTT $11.92
  • Technical
  • Relative Strength Index (RSI)
  • ACET 43.24
  • INTT 60.86
  • Support Level
  • ACET $0.72
  • INTT $6.73
  • Resistance Level
  • ACET $0.84
  • INTT $7.35
  • Average True Range (ATR)
  • ACET 0.06
  • INTT 0.33
  • MACD
  • ACET -0.02
  • INTT 0.06
  • Stochastic Oscillator
  • ACET 0.00
  • INTT 71.43

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About INTT inTest Corporation

inTest Corp is a supplier of test and process solutions for use in manufacturing and testing across a range of markets including automotive, defense/aerospace, industrial, medical, semiconductor and telecommunications. The company manages its business as three operating segments which is also their reporting units that includes Electronic Test, Environmental Technologies and Process Technologies. Electronic Test (which includes semiconductor test equipment, flying probe and in-circuit testers), Environmental Technologies (which includes its thermal test, process and storage products) and Process Technologies (which includes induction heating and video imaging products). The company operates their business and sells its products both domestically and internationally.

Share on Social Networks: